Drug Discovery World

MAY 25, 2023

DNA Script: SYNTAX DNA printing platform Using the company’s EDS technology, the SYNTAX platform can synthesise up to 96 highly accurate, ready-to-use DNA oligos with maximum lengths of up to 120nt in less than 24 hours in the laboratory.

Production 130

Production DNA Assay Development Drugs 130

Drug Discovery World

SEPTEMBER 29, 2022

During a 2021 webinar on optimising assay development for hit identification, a survey asked over 50 drug discovery scientists, “Which goal is the highest priority when developing a drug discovery assay?”. Designing DEL libraries has benefited from the development of AI to model compounds based on binding pockets.

Small Molecule 130

Small Molecule Assay Development DNA Biochemical Assays 130

Drug Discovery World

AUGUST 29, 2024

Enzyme-linked immunosorbent assays Abcam’s enzyme-linked immunosorbent assay (ELISA)-based tools and reagents are designed to be flexible as they can be used on multiple platforms and adapted to automatable systems and liquid handlers.

Small Molecule 148

Small Molecule Drugs Protein Expression Assay Development 148

Sygnature Discovery

JUNE 17, 2024

Comprehensive Assay Development for Diverse Applications Our team here at Sygnature Discovery, comprised of expert biophysicists, is highly experienced in a variety of target classes and drug modalities. Sygnature Discovery’s Biophysical Assay Development Capabilities: 1.

Biophysical Assays 52

Biophysical Assays Screening Hits Fragment Screening Assay Development 52

Drug Discovery World

JANUARY 19, 2023

This paid-for advertorial by Catalent appeared in DDW Volume 24 – Issue 1, Winter 2022/2023 One significant challenge in the manufacturing of cell and gene therapies is the production of high-quality plasmid DNA (pDNA). Figure 1: The integrated development pathway for cell and gene therapies. billion by 2030 (BioSpace, 11 August 2022).

DNA 130

DNA Therapies Assay Development Production 130

Drug Discovery World

DECEMBER 14, 2023

But it comes with surface charge that will absorb proteins, DNA, and other things, unless you do something to treat that surface. Aurora tried to make plates out of polystyrene and could not make them get a signal to noise ratio that was appropriate to conduct viable assays.

Laboratories 130

Laboratories Production Science Packaging 130

Agency IQ

JULY 21, 2023

The next chapter in the ctDNA story: Still promising, not ready for prime time A recent workshop summed up the state of play for circulating tumor DNA. As dying cancer cells degrade, their cell contents are released into the patient’s circulation, affording the possibility of detecting fragments of DNA that are unique to the cancer.

FDA 40

FDA Clinical Trials DNA Treatment 40